Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | V560G |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | KIT V560G lies within the juxtamembrane domain (exon 11) of the Kit protein (PMID: 9438854). V560G confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and activation of the Jak/Stat pathway (PMID: 7691885, PMID: 23777495, PMID: 31484543), and leads to mislocalization of Kit to endolysosomes in cell culture (PMID: 31484543). |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT V560G KIT mutant KIT exon11 KIT V560G |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727447T>G |
cDNA | c.1679T>G |
Protein | p.V560G |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005265740.1 | chr4:g.54727444T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727444T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727447T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727444T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727447T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727447T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727447T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54727444T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727444T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727444T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727447T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727447T>G | c.1679T>G | p.V560G | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT V560G | mast cell neoplasm | sensitive | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gleevec (imatinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |
KIT V560G | mast cell neoplasm | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |
KIT V560G | Advanced Solid Tumor | sensitive | Nilotinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing KIT V560G demonstrated inhibition of cell proliferation and tumor regression both in culture and in vivo when treated with Tasigna (nilotinib) (PMID: 20442311). | 20442311 |
KIT V560G | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, cells expressing KIT V560G demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
KIT V560G | mast cell neoplasm | sensitive | Regorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Stivarga (regorafenib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |
KIT V560G | mast cell neoplasm | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |
KIT V560G | mast cell neoplasm | sensitive | Avapritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Ayvakit (avapritinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |
KIT V560G | mast-cell leukemia | sensitive | Avapritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and proliferation of mast cell leukemia cells harboring KIT V560G in culture (PMID: 29093181). | 29093181 |
KIT V560G | mast cell neoplasm | sensitive | Ripretinib | Preclinical - Cell culture | Actionable | In a preclinical study, Qinlock (ripretinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |